OGN Stock Alert: Organon & Co. Shareholders with Large Losses Should Contact Robbins LLP for Information on Leading the Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors about its capital allocation strategy, particularly regarding its debt reduction efforts and dividend payouts [1][2][3]. Allegations - The lawsuit claims that during the class period, Organon prioritized its capital allocation strategy through regular dividends, stating it was a "1 capital allocation priority" while concealing the importance of its debt reduction strategy after acquiring Dermavant [2][3]. - The complaint highlights that the regular quarterly dividend was reduced by 70%, indicating a significant shift in the company's financial strategy that was not disclosed to investors [3]. Impact of Disclosure - On May 1, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 to$0.02, which was intended to recapture capital for the company. This announcement led to a decline in the stock price from $12.93 to$9.45, representing a drop of over 27% [4]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs. They can also choose to remain absent class members without participating in the case [5]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [6].